Fraser Claire, a director at Becton Dickinson & Co. ($BDX), sold shares on the open market twice in the last 365 days for a total of about $338,000. Her most recent sale occurred on September 10, 2025. These sales rank 7,319th among 11,678 individual insiders, below the average sale amount of $8.6 million and 6.4 transactions per insider. Fraser Claire made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 25, 2026 | WATERS CORP /DE/ | $WAT | Fraser Claire | Director | A | Common Stock | 358 | $0.00 | 489.0000 | 59,763,000 | 273.28% | 0.00% |
| Feb. 25, 2026 | WATERS CORP /DE/ | $WAT | Fraser Claire | Director | A | Stock Option (Right to Buy) | 877 | $0.00 | 877.0000 | 59,763,000 | 9999.99% | 0.00% |
| Sept. 10, 2025 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | S | Common Stock | 917 | $187.50 | 22,226.0000 | 288,693,000 | 3.96% | 0.00% |
| Aug. 8, 2025 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | S | Common Stock | 863 | $192.30 | 23,143.0000 | 288,693,000 | 3.59% | 0.00% |
| July 1, 2025 | Seres Therapeutics, Inc. | $MCRB | Fraser Claire | Not found | A | Stock Option (right to buy) | 6452 | $0.00 | 6,452.0000 | 174,358,753 | 9999.99% | 0.00% |
| April 10, 2025 | Seres Therapeutics, Inc. | $MCRB | Fraser Claire | Not found | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 174,358,753 | 9999.99% | 0.06% |
| Jan. 28, 2025 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | A | Common Stock | 930 | $0.00 | 24,006.0000 | 290,389,000 | 4.03% | 0.00% |
| April 4, 2024 | Seres Therapeutics, Inc. | $MCRB | Fraser Claire | Not found | A | Stock Option (right to buy | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 23, 2024 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | A | Common Stock | 900 | $0.00 | 22,696.0000 | 288,392,000 | 4.13% | 0.00% |
| Aug. 28, 2023 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | S | Common Stock | 848 | $281.66 | 21,608.0000 | 0 | 3.78% | 0.00% |
| June 22, 2023 | Seres Therapeutics, Inc. | $MCRB | Fraser Claire | Director | A | Stock Option (right to buy) | 35000 | $0.00 | 35,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 26, 2023 | BECTON DICKINSON & CO | $BDX | Fraser Claire | Director | A | Common Stock | 848 | $0.00 | 22,311.0000 | 0 | 3.95% | 0.00% |
| Jan. 4, 2023 | Seres Therapeutics, Inc. | $MCRB | Fraser Claire | Director | A | Stock Option (right to buy) | 48000 | $0.00 | 48,000.0000 | 0 | 9999.99% | 0.00% |